On February 2, 2026, the Scientific Committee on Consumer Safety (SCCS) adopted its final scientific opinion (SCCS/1680/25) on the safety of certain prostaglandin analogues when used in cosmetic products intended for eyelash and eyebrow enhancement. The prostaglandin analogues evaluated include Methylamido-Dihydro-Noralfaprostal (MDN) (CAS 155206-01-2), Isopropyl Cloprostenate (IPCP) (CAS 157283-66-4), and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) (CAS 1185851-52-8). The opinion followed a minimum eight-week public commenting period and subsequent scientific review.
The SCCS assessed toxicological data, exposure information, and health risks associated with these compounds. Based on available evidence, the Committee concluded that none of the evaluated prostaglandin analogues can be considered safe for use in cosmetic products intended to promote eyelash and eyebrow growth, given their potent biological activity even at low concentrations and a lack of sufficient data to exclude potential adverse effects, including reproductive or developmental toxicity.
The opinion provides detailed hazard evaluations and is intended to inform the European Commission’s regulatory considerations under the EU Cosmetics Regulation (Regulation (EC) No 1223/2009).

Consumer News Tags
Scientific Committee on Consumer Safety (SCCS); Prostaglandin Analogues; Cosmetic Safety; Eyelash and Eyebrow Products; Methylamido-Dihydro-Noralfaprostal; Isopropyl Cloprostenate; Dechloro Dihydroxy Difluoro Ethylcloprostenolamide; Toxicological Assessment; Cosmetic Regulation